-
公开(公告)号:US20080286288A1
公开(公告)日:2008-11-20
申请号:US11980495
申请日:2007-10-31
IPC分类号: A61K39/395 , C12N15/11 , C12N15/00 , C12N5/06 , A61P43/00 , G01N33/53 , C12P21/04 , C07K16/18
CPC分类号: C07K16/22 , A01K2217/05 , A01K2217/075 , A61K38/00 , A61K48/00 , A61K2039/505 , C07K14/52 , C07K16/24 , C07K2317/21 , C07K2317/622 , C12N2799/026 , G01N33/574 , G01N33/74 , Y02A50/41 , Y02A50/422 , Y10S435/81
摘要: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
摘要翻译: 公开了人VEGF-2抗体,抗体片段或其变体。 还提供了产生这种抗体的方法。 本发明涉及用于预防,治疗或改善疾病或病症的方法和组合物,包括向动物(优选人)施用有效量的一种或多种VEGF-2抗体或其片段或变体。
-
公开(公告)号:US20080213886A1
公开(公告)日:2008-09-04
申请号:US11429374
申请日:2006-05-08
CPC分类号: C07K14/765 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K38/00 , A61K38/04 , A61K38/17 , A61K38/28 , A61K39/21 , C07K7/06 , C07K14/005 , C07K14/435 , C07K14/4713 , C07K14/4723 , C07K14/475 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/57563 , C07K14/5759 , C07K14/585 , C07K14/59 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/7151 , C07K14/82 , C07K16/00 , C07K16/241 , C07K16/26 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/20 , C07K2319/30 , C07K2319/31 , C12N7/00 , C12N9/0006 , C12N9/0008 , C12N15/62 , C12N2501/335 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12Y101/01105 , C12Y102/01 , C12Y207/01095
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
摘要翻译: 本发明包括白蛋白融合蛋白。 编码本发明的白蛋白融合蛋白的核酸分子也包括在本发明中,载体含有这些核酸,用这些核酸载体转化的宿主细胞,以及制备本发明的白蛋白融合蛋白并使用这些核酸的方法 酸,载体和/或宿主细胞。 另外,本发明包括包含白蛋白融合蛋白的药物组合物以及使用本发明的白蛋白融合蛋白来治疗,预防或改善疾病,病症或病症的方法。
-
公开(公告)号:US20080167238A1
公开(公告)日:2008-07-10
申请号:US11929912
申请日:2007-10-30
CPC分类号: C07K14/4713 , C07K14/765
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US20080161243A1
公开(公告)日:2008-07-03
申请号:US11929714
申请日:2007-10-30
CPC分类号: C07K14/765 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K38/00 , A61K38/04 , A61K38/17 , A61K38/28 , A61K39/21 , C07K7/06 , C07K14/005 , C07K14/435 , C07K14/4713 , C07K14/4723 , C07K14/475 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/57563 , C07K14/5759 , C07K14/585 , C07K14/59 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/7151 , C07K14/82 , C07K16/00 , C07K16/241 , C07K16/26 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/20 , C07K2319/30 , C07K2319/31 , C12N7/00 , C12N9/0006 , C12N9/0008 , C12N15/62 , C12N2501/335 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12Y101/01105 , C12Y102/01 , C12Y207/01095
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US07368527B2
公开(公告)日:2008-05-06
申请号:US10105299
申请日:2002-03-26
申请人: Craig A. Rosen , Steven M. Ruben
发明人: Craig A. Rosen , Steven M. Ruben
IPC分类号: C07K14/47
CPC分类号: A61K38/17 , C07K14/47 , G01N33/566 , G01N2500/00 , Y02A50/401
摘要: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
摘要翻译: 本发明涉及人分泌多肽和编码所述多肽的分离的核酸分子,其可用于诊断和治疗与所述人分泌蛋白相关的疾病,病症和/或病症。 结合这些多肽的抗体也包括在本发明中。 本发明还包括载体,宿主细胞,以及用于产生所述多核苷酸,多肽和/或抗体的重组和合成方法。 本发明还包括用于鉴定本发明的多核苷酸和多肽的激动剂和拮抗剂的筛选方法。 本发明还包括用于抑制或增强本发明多肽的产生和功能的方法和组合物。
-
86.
公开(公告)号:US07364865B2
公开(公告)日:2008-04-29
申请号:US11381977
申请日:2006-05-05
申请人: Reiner L. Gentz , Brent L. Kreider , Jun Zhang , Michael Antonaccio , Donna Mendrick , Pablo Jimenez , Vikram Patel , Craig A. Rosen , Mark D. Adams , Haodong Li , Steven M. Ruben
发明人: Reiner L. Gentz , Brent L. Kreider , Jun Zhang , Michael Antonaccio , Donna Mendrick , Pablo Jimenez , Vikram Patel , Craig A. Rosen , Mark D. Adams , Haodong Li , Steven M. Ruben
CPC分类号: G01N33/6863 , A61K38/00 , A61K48/00 , C07K1/113 , C07K1/36 , C07K14/50 , C07K14/521 , C07K14/523 , C07K16/24 , C07K2319/00 , C12N15/72 , C12N2799/026 , G01N2333/52
摘要: There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine β8 (CKβ8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-γ and chemokine β1(CKβ1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.
摘要翻译: 公开了使用编码人骨髓祖细胞抑制因子-1(MPIF-1)多肽(以前称为MIP-3和趋化因子β8(CKbeta8或ckb-8))的分离的核酸分子的治疗组合物和方法。 人单核细胞集落抑制因子(M-CIF)多肽(以前称为MIP1-γ和趋化因子β1(CKbeta1或ckb-1))和巨噬细胞抑制蛋白-4(MIP-4)以及MPIF-1 ,M-CIF和/或MIP-4多肽本身,以及用于产生它们的载体,宿主细胞和重组方法。
-
公开(公告)号:US07238667B2
公开(公告)日:2007-07-03
申请号:US11429373
申请日:2006-05-08
IPC分类号: A61K38/38 , C07K14/76 , C07K14/765
CPC分类号: C07K14/765 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K38/00 , A61K38/04 , A61K38/17 , A61K38/28 , A61K39/21 , C07K7/06 , C07K14/005 , C07K14/435 , C07K14/4713 , C07K14/4723 , C07K14/475 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/57563 , C07K14/5759 , C07K14/585 , C07K14/59 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/7151 , C07K14/82 , C07K16/00 , C07K16/241 , C07K16/26 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/20 , C07K2319/30 , C07K2319/31 , C12N7/00 , C12N9/0006 , C12N9/0008 , C12N15/62 , C12N2501/335 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12Y101/01105 , C12Y102/01 , C12Y207/01095
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.
摘要翻译: 本发明包括白蛋白融合蛋白。 编码本发明的白蛋白融合蛋白的核酸分子也包括在本发明中,载体含有这些核酸,用这些核酸载体转化的宿主细胞,以及制备本发明的白蛋白融合蛋白并使用这些核酸的方法 酸,载体和/或宿主细胞。 另外,本发明包括包含白蛋白融合蛋白的药物组合物以及使用本发明的白蛋白融合蛋白来治疗,预防或改善疾病,紊乱或病症的方法。
-
公开(公告)号:US07208582B2
公开(公告)日:2007-04-24
申请号:US10120414
申请日:2002-04-12
CPC分类号: C07K16/22 , A01K2217/05 , A01K2217/075 , A61K38/00 , A61K48/00 , A61K2039/505 , C07K14/52 , C07K16/24 , C07K2317/21 , C07K2317/622 , C12N2799/026 , G01N33/574 , G01N33/74 , Y02A50/41 , Y02A50/422 , Y10S435/81
摘要: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
摘要翻译: 公开了人VEGF-2抗体,抗体片段或其变体。 还提供了产生这种抗体的方法。 本发明涉及用于预防,治疗或改善疾病或病症的方法和组合物,包括向动物(优选人)施用有效量的一种或多种VEGF-2抗体或其片段或变体。
-
公开(公告)号:US07175988B2
公开(公告)日:2007-02-13
申请号:US10067800
申请日:2002-02-08
申请人: Viktor Roschke , Craig A. Rosen , Steven M. Ruben
发明人: Viktor Roschke , Craig A. Rosen , Steven M. Ruben
IPC分类号: G01N33/53 , C07K16/00 , A61K39/395
CPC分类号: C07K14/7158 , A01K2217/05 , A01K2217/075 , A61K38/00 , A61K48/00 , A61K2039/505 , C07K16/24 , C07K16/2866 , C07K2319/00 , C12N2799/026
摘要: The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.
摘要翻译: 本发明涉及一种称为人G蛋白趋化因子受体(CCR5)HDGNR10的新型人类蛋白质,以及编码该蛋白质的分离的多核苷酸。 本发明还涉及结合人G蛋白趋化因子受体(CCR5)HDGNR10的人抗体和编码那些抗体的多核苷酸。 还提供了用于产生人G蛋白趋化因子受体(CCR5)HDGNR10和人抗人G蛋白趋化因子受体(CCR5)HDGNR10抗体的载体,宿主细胞,抗体和重组方法。 本发明还涉及用于诊断和治疗与该新型人蛋白质和这些新型人抗体相关的疾病,病症和/或病症的诊断和治疗方法。
-
公开(公告)号:US07169566B2
公开(公告)日:2007-01-30
申请号:US10979092
申请日:2004-11-02
申请人: Jian Ni , Steven M. Ruben , Laurie A. Brewer , Reiner L. Gentz , Craig A. Rosen
发明人: Jian Ni , Steven M. Ruben , Laurie A. Brewer , Reiner L. Gentz , Craig A. Rosen
CPC分类号: C12N9/6489 , A61K38/00 , C07K14/47 , C07K14/705 , C07K14/70535 , C12N9/00 , C12N9/6475 , C12N9/6491 , C12N2799/026
摘要: The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.
摘要翻译: 本发明涉及新型金属蛋白酶样蛋白质。 特别地,提供了分离的核酸分子,其编码人类TACE样和基质溶素样蛋白。 TACE样和基质溶素样多肽也可以作为载体,宿主细胞和用于制备它们的重组方法提供。 本发明进一步涉及用于鉴定TACE样和基质溶素样活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测癌症的诊断方法和癌症的治疗方法以及特征在于这些金属蛋白酶过度或过量生产的其它病症。
-
-
-
-
-
-
-
-
-